Ionis Pharmaceuticals submitted a label expansion and the FDA said yes. Replimune has now been rejected twice on the same melanoma drug and just got the FDA to accept a third attempt, this time with an advisory committee meeting attached. One company is celebrating a smooth approval. The other is celebrating an agency that will at least listen again.
Ionis Won FDA Approval for Tryngolza in a Market 3.6 Million Patients Larger Than Its First Indication
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced on June 24 that the FDA approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, defined as triglyceride levels of 500 mg/dL or higher. The approval was based on the Phase 3 CORE and CORE2 studies, which enrolled 1,061 participants and showed up to 72% reductions in fasting triglycerides at six months, sustained through 12 months, alongside up to 91% fewer acute pancreatitis events versus placebo. The drug is self-administered once monthly via autoinjector and will be available for this indication in July.
Tryngolza was already approved for familial chylomicronemia syndrome, a rare form of severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide, a synthetic strand of nucleic acid designed to reduce production of a specific protein, in this case apolipoprotein C-III, which normally inhibits the clearance of triglycerides from the bloodstream. The new approval expands the addressable population from the rare FCS subset to the broader sHTG population, estimated at 3.6 million people in the US, of whom roughly 1 million are considered high-risk. William Blair analysts raised their peak sales forecast to $3 billion on the news and called the indication a likely meaningful contributor to Ionis’s 2028 cash flow breakeven target.
CEO Brett Monia called it Ionis’s first independent commercial launch in a prevalent disease, distinct from the company’s historical role as an R&D partner that licensed assets to larger partners. The approval did not require an advisory committee meeting, did not follow a prior rejection, and arrived on the standard review track. That smoothness is itself the story: a company built on antisense chemistry converting a rare-disease platform into a mainstream cardiometabolic franchise without regulatory friction.
The FDA Accepted Replimune’s Third Attempt at Approving RP1, With an Advisory Committee Attached
Replimune Group, Inc. (Nasdaq: REPL) announced on June 26 that the FDA accepted for review the resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma, classifying it as a complete, Class 1 response with a target action date of August 2, 2026. The FDA also notified the company to expect an advisory committee meeting in late July, ahead of that decision.
This is not Replimune’s first attempt. The company originally submitted the BLA in late 2024 and received a Complete Response Letter on July 22, 2025. The first resubmission was accepted in October 2025 with a PDUFA date of April 10, 2026, under a Class II timeline, but the agency issued a second CRL on that same deadline. Reported regulatory friction stemmed from disagreement within FDA leadership over whether RP1 adequately demonstrated its contribution of effect in a single-arm study design, compounded by review-team turnover and limited sponsor interaction during the process. This June submission is the third attempt.
RP1 seeks accelerated approval based on the Phase 2 IGNYTE trial, which enrolled 140 patients with advanced melanoma who had confirmed progression on prior anti-PD-1 therapy. RP1 is an oncolytic immunotherapy built on a genetically engineered herpes simplex virus designed to replicate within tumor cells and stimulate a systemic immune response against the cancer, reporting a 34% objective response rate and 24.8-month median duration of response in combination with nivolumab, against a 4.4-month median progression-free survival on prior PD-1 therapy alone. A confirmatory trial, IGNYTE-3, is already underway. Whether a single-arm trial with these response numbers is enough to satisfy the FDA’s contribution-of-effect concerns a third time is exactly what the late-July advisory committee will weigh in on.
Replimune Advisory Committee Meeting, Tryngolza July Launch, and IGNYTE-3 Confirmatory Trial Progress
Replimune advisory committee meeting: scheduled for late July, ahead of the August 2 PDUFA date. The committee’s vote and the specific concerns raised will be the clearest signal yet on whether this third resubmission breaks the pattern of the first two.
Tryngolza commercial launch: available for the sHTG indication starting in July. Watch early prescription data and payer coverage decisions, which will be the first real test of whether William Blair’s $3 billion peak sales estimate is achievable.
IGNYTE-3 confirmatory trial: running in parallel to the BLA review. Watch for any interim data disclosure, since a strong confirmatory readout would strengthen Replimune’s case regardless of how the August 2 decision goes.
Sources
- Ionis Pharmaceuticals SEC Form 8-K: TRYNGOLZA approved by FDA for severe hypertriglyceridemia, June 24 2026
- BioSpace: Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use, William Blair $3 billion peak sales estimate, June 2026
- BioPharma Dive: Ionis, with new FDA nod, hits a commercial inflection point, June 2026
- Replimune Group SEC Form 8-K: FDA acceptance of RP1 BLA resubmission for advanced melanoma, August 2 2026 goal date, June 26 2026
- Dermatology Times: FDA accepts third RP1 BLA resubmission for advanced melanoma, regulatory history and IGNYTE trial data, June 2026
- CancerNetwork: FDA accepts RP1 BLA resubmission for advanced melanoma, accelerated approval pathway, June 26 2026
Editorial Disclosure
This analysis is based entirely on publicly available information including company press releases sourced directly from company websites, SEC filings, and named wire services. Securities discussed include Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Replimune Group, Inc. (Nasdaq: REPL). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. RP1 (vusolimogene oderparepvec) is an investigational therapy and has not been approved by the FDA for any indication; this is the company’s third BLA submission following two prior Complete Response Letters, and FDA acceptance for review does not indicate or guarantee eventual approval. The IGNYTE trial supporting the BLA was a single-arm Phase 2 study without a randomized control arm, a design limitation the FDA has previously cited as a concern regarding demonstrated contribution of effect; results from this trial design carry inherent limitations in predicting outcomes versus standard of care. William Blair’s $3 billion peak sales estimate for Tryngolza represents that firm’s own analyst opinion and is not aktiego.com’s view or a guarantee of future revenue. Tryngolza’s sHTG indication clinical data is sourced to the Phase 3 CORE and CORE2 trials and is caveated to the specific study populations in which it was generated. Both securities carry significant investment risk including total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
Watch on YouTube
